HM-CINAC, Hospital Universitario HM Puerta del Sur, Mostoles and Medical School, CEU-San Pablo University, Madrid, Spain.
CIBERNED, Instituto Carlos III, Madrid, Spain.
Mov Disord. 2017 Apr;32(4):530-537. doi: 10.1002/mds.26947. Epub 2017 Mar 3.
Long-term levodopa (l-dopa) treatment is associated with the development of l-dopa-induced dyskinesias in the majority of patients with Parkinson disease (PD). The etiopathogonesis and mechanisms underlying l-dopa-induced dyskinesias are not well understood.
We used striatal optogenetic stimulation to induce dyskinesias in a hemiparkinsonian model of PD in rats. Striatal dopamine depletion was induced unilaterally by 6-hydroxydopamine injection into the medial forebrain bundle. For the optogenetic manipulation, we injected adeno-associated virus particles expressing channelrhodopsin to stimulate striatal medium spiny neurons with a laser source.
Simultaneous optical activation of medium spiny neurons of the direct and indirect striatal pathways in the 6-hydroxydopamine lesion but l-dopa naïve rats induced involuntary movements similar to l-dopa-induced dyskinesias, labeled here as optodyskinesias. Noticeably, optodyskinesias were facilitated by l-dopa in animals that did not respond initially to the laser stimulation. In general, optodyskinesias lasted while the laser stimulus was applied, but in some instances remained ongoing for a few seconds after the laser was off. Postmortem tissue analysis revealed increased FosB expression, a molecular marker of l-dopa-induced dyskinesias, primarily in medium spiny neurons of the direct pathway in the dopamine-depleted hemisphere.
Selective optogenetic activation of the dorsolateral striatum elicits dyskinesias in the 6-hydroxydopamine rat model of PD. This effect was associated with a preferential activation of the direct striato-nigral pathway. These results potentially open new avenues in the understanding of mechanisms involved in l-dopa-induced dyskinesias. © 2017 International Parkinson and Movement Disorder Society.
长期左旋多巴(l-dopa)治疗与大多数帕金森病(PD)患者的 l-dopa 诱导运动障碍的发展有关。l-dopa 诱导运动障碍的病因发病机制和机制尚不清楚。
我们使用纹状体光遗传学刺激在大鼠 PD 的半帕金森模型中诱导运动障碍。通过将 6-羟多巴胺注射到中脑束中来单侧诱导纹状体多巴胺耗竭。对于光遗传学操作,我们注射表达通道视紫红质的腺相关病毒颗粒,用激光源刺激纹状体中间神经元。
在 6-羟多巴胺损伤但 l-dopa 未治疗的大鼠中,直接和间接纹状体通路的中间神经元同时光激活诱导类似于 l-dopa 诱导运动障碍的不自主运动,这里称为光运动障碍。值得注意的是,在最初对激光刺激没有反应的动物中,l-dopa 促进了光运动障碍。通常,光运动障碍持续应用激光刺激,但在某些情况下,激光关闭后仍持续数秒。死后组织分析显示,在多巴胺耗竭半球的直接通路中的中间神经元中,FosB 表达增加,这是 l-dopa 诱导运动障碍的分子标志物。
选择性光遗传学激活背外侧纹状体在 6-羟多巴胺 PD 大鼠模型中引发运动障碍。这种效应与直接纹状体-黑质通路的优先激活有关。这些结果可能为理解 l-dopa 诱导运动障碍所涉及的机制开辟新途径。© 2017 年国际帕金森病和运动障碍协会。